Advertisement

Laser Synergism with Drug Eluting Balloon for Treatment of In-Stent Restenosis in the Lower Extremities

  • Jos C. van den BergEmail author

Abstract

Restenosis, and in particular in-stent restenosis, remains a problem that significantly affects mid- and long-term outcome of all endovascular procedures, and especially procedures that involve the superficial femoral and popliteal artery. This chapter will provide a description of the process of (in-stent) restenosis with special attention to the histopathological changes that occur. Furthermore it will give an overview of the current status of drug-eluting balloon technology. It will describe the technique of the treatment of in-stent restenosis of the infrainguinal arteries, using a combined technique of laser debulking (atherectomy) followed by drug-eluting balloon angioplasty. Personal experience as well as the results of this technique as described in the literature will be discussed. A comparison with other techniques such as drug-eluting balloon angioplasty as stand-alone therapy or mechanical atherectomy as single therapy will be made. It is concluded that in the treatment of in-stent restenosis, debulking is probably key. There is a growing body of evidence that by adding drug-eluting balloon angioplasty to debulking results can be achieved that compare favorable to those described in the literature that were obtained with standard balloon angioplasty, cutting-balloon angioplasty or debulking alone.

Keywords

Laser Peripheral arterial disease Infra-inguinal arteriesm In-stent restenosis Atherectomy Drug-eluting balloons 

References

  1. 1.
    Diehm NA, Hoppe H, Do DD. Drug eluting balloons. Tech Vasc Interv Radiol. 2010;13(1):59–63.CrossRefPubMedGoogle Scholar
  2. 2.
    Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3(3):267–76.CrossRefPubMedGoogle Scholar
  3. 3.
    Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115(21):2745–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Siablis D, Karnabatidis D, Katsanos K, Diamantopoulos A, Spiliopoulos S, Kagadis GC, et al. Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J Vasc Interv Radiol. 2009;20(9):1141–50.CrossRefPubMedGoogle Scholar
  5. 5.
    Dick P, Sabeti S, Mlekusch W, Schlager O, Amighi J, Haumer M, et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience. Radiology. 2008;248(1):297–302.CrossRefPubMedGoogle Scholar
  6. 6.
    Karthik S, Tuite DJ, Nicholson AA, Patel JV, Shaw DR, McPherson SJ, et al. Cryoplasty for arterial restenosis. Eur J Vasc Endovasc Surg. 2007;33(1):40–3.CrossRefPubMedGoogle Scholar
  7. 7.
    Zeller T, Rastan A, Sixt S, Schwarzwalder U, Schwarz T, Frank U, et al. Long-term results after directional atherectomy of femoro-popliteal lesions. J Am Coll Cardiol. 2006;48(8):1573–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Sullivan TM, Ainsworth SD, Langan EM, Taylor S, Snyder B, Cull D, et al. Effect of endovascular stent strut geometry on vascular injury, myointimal hyperplasia, and restenosis. J Vasc Surg. 2002;36(1):143–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Carter AJ, Laird JR, Farb A, Kufs W, Wortham DC, Virmani R. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J Am Coll Cardiol. 1994;24(5):1398–405.CrossRefPubMedGoogle Scholar
  10. 10.
    Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99(1):44–52.CrossRefPubMedGoogle Scholar
  11. 11.
    Farb A, Virmani R, Atkinson JB, Kolodgie FD. Plaque morphology and pathologic changes in arteries from patients dying after coronary balloon angioplasty. J Am Coll Cardiol. 1990;16(6):1421–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Adiguzel E, Ahmad PJ, Franco C, Bendeck MP. Collagens in the progression and complications of atherosclerosis. Vasc Med. 2009;14(1):73–89.CrossRefPubMedGoogle Scholar
  13. 13.
    Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105(25):2974–80.CrossRefPubMedGoogle Scholar
  14. 14.
    Inoue S, Koyama H, Miyata T, Shigematsu H. Pathogenetic heterogeneity of in-stent lesion formation in human peripheral arterial disease. J Vasc Surg. 2002;35(4):672–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Iida O, Uematsu M, Soga Y, Hirano K, Suzuki K, Yokoi H, et al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses. Catheter Cardiovasc Interv. 2011;78(4):611–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Osherov AB, Gotha L, Cheema AN, Qiang B, Strauss BH. Proteins mediating collagen biosynthesis and accumulation in arterial repair: novel targets for anti-restenosis therapy. Cardiovasc Res. 2011;91(1):16–26.CrossRefPubMedGoogle Scholar
  17. 17.
    Farb A, Kolodgie FD, Hwang JY, Burke AP, Tefera K, Weber DK, et al. Extracellular matrix changes in stented human coronary arteries. Circulation. 2004;110(8):940–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119(23):2986–94.CrossRefPubMedGoogle Scholar
  19. 19.
    Karnabatidis D, Katsanos K, Spiliopoulos S, Diamantopoulos A, Kagadis GC, Siablis D. Incidence, anatomical location, and clinical significance of compressions and fractures in infrapopliteal balloon-expandable metal stents. J Endovasc Ther. 2009;16(1):15–22.CrossRefPubMedGoogle Scholar
  20. 20.
    Waksman R, Pakala R. Drug-eluting balloon: the comeback kid? Circ Cardiovasc Interv. 2009;2(4):352–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Wiskirchen J, Schober W, Schart N, Kehlbach R, Wersebe A, Tepe G, et al. The effects of paclitaxel on the three phases of restenosis: smooth muscle cell proliferation, migration, and matrix formation: an in vitro study. Invest Radiol. 2004;39(9):565–71.CrossRefPubMedGoogle Scholar
  22. 22.
    Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110(7):810–4.CrossRefPubMedGoogle Scholar
  23. 23.
    Cremers B, Speck U, Kaufels N, Mahnkopf D, Kuhler M, Bohm M, et al. Drug-eluting balloon: very short-term exposure and overlapping. Thromb Haemost. 2009;101(1):201–6.PubMedGoogle Scholar
  24. 24.
    Schmidt A, Zeller T, Sievert H, Krankenberg H, Torsello G, Stark MA, et al. Photoablation using the turbo-booster and excimer laser for in-stent restenosis treatment: twelve-month results from the PATENT study. J Endovasc Ther. 2014;21(1):52–60.CrossRefPubMedGoogle Scholar
  25. 25.
    Gandini R, Del GC, Merolla S, Morosetti D, Pampana E, Simonetti G. Treatment of chronic SFA in-stent occlusion with combined laser atherectomy and drug-eluting balloon angioplasty in patients with critical limb ischemia: a single-center, prospective, randomized study. J Endovasc Ther. 2013;20(6):805–14.CrossRefPubMedGoogle Scholar
  26. 26.
    Van Den Berg JC, Pedrotti M, Canevascini R, Chimchila CS, Giovannacci L, Rosso R. Endovascular treatment of in-stent restenosis using excimer laser angioplasty and drug eluting balloons. J Cardiovasc Surg (Torino). 2012;53(2):215–22.Google Scholar
  27. 27.
    Tosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59(1):16–23.CrossRefPubMedGoogle Scholar
  28. 28.
    Van Den Berg JC. Commentary: laser debulking and drug-eluting balloons for in-stent restenosis: a light at the end of the tunnel? J Endovasc Ther. 2013;20(6):815–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol. 2008;97(10):773–81.CrossRefPubMedGoogle Scholar
  30. 30.
    Stabile E, Virga V, Salemme L, Cioppa A, Ambrosini V, Sorropago G, et al. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol. 2012;60(18):1739–42.CrossRefPubMedGoogle Scholar
  31. 31.
    Sixt S, Carpio Cancino OG, Treszl A, Beschorner U, Macharzina R, Rastan A, et al. Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries. J Vasc Surg. 2013;58(3):682–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Trentmann J, Charalambous N, Djawanscher M, Schafer JP, Jahnke T. Safety and efficacy of directional atherectomy for the treatment of in-stent restenosis of the femoropopliteal artery. J Cardiovasc Surg (Torino). 2010;51(4):551–60.Google Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  1. 1.Service of Interventional RadiologyOspedale Regionale di LuganoLuganoSwitzerland

Personalised recommendations